ASN Kidney Week 2026: key results and trends

The proportion of patients achieving flare-free, corticosteroid-free complete remission was higher with INEB vs PBO (57.1% vs 21.1%; odds ratio 5.08, nominal p=0.0281).

At Week 24, in enlicitide-treated pts with eGFR <60, 80.5% achieved LDL-C <70 mg/dL (81.5% eGFR ≥60) and 74.9% achieved <55 mg/dL (74.7% eGFR ≥60), all significantly greater than placebo ( P <0.001).

Fluid retention adverse events occurred in 7 (10.3%) pts on atrasentan vs 4 (5.7%) on placebo; none led to discontinuation.

More pts in the SPAR vs IRB arm achieved CR (20% vs 6%), UPCR <0.7 g/g (43% vs 22%), and <1.5 g/g (79% vs 50%); nominal P <.01 for all thresholds.

AE rates were similar (iptacopan: 92.2% vs PBO: 89.1%); most were mild to moderate.

Of the 182 patients in each arm of the NefIgArd trial, significantly more patients receiving nefecon (61%) than placebo (33%) experienced a reduction in eGFR loss to <1 mL/min/1.73 m 2 at 9 months.

Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively.

At month 6 the pooled pairwise comparison of placebo versus lumasiran was estimated at -11.32% change in plasma oxalate without significant a treatment effect (p= 0.174, 95% CI [-27.64, 5.00]).